Evidence map›Paper›PMID 29020502›Full record

ReviewCancer biology & therapy2017

Persistence of DNA adducts, hypermutation and acquisition of cellular resistance to alkylating agents in glioblastoma.

R J Head, M F Fay, L Cosgrove, K Y C Fung, D Rundle-Thiele, J H Martin

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer biology & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. DNA Mismatch Repair and its Role in Huntington's Disease.Journal of Huntington's disease · 2021
    Review
  5. The rationale of dose-response curves in selecting cancer drug dosing.British journal of clinical pharmacology · 2019
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

R J Heada University of South Australia , Adelaide , SA , Australia.
M F Fayb University of Newcastle , Newcastle , NSW , Australia.
L Cosgrovee CSIRO Health & Biosecurity , Adelaide , SA , Australia.
K Y C Fungf CSIRO Health & Biosecurity , N Ryde , NSW , Australia.
D Rundle-Thieleg School of Medicine, Flinders University , Bedford Park , SA , Australia.
J H Martinb University of Newcastle , Newcastle , NSW , Australia.
CSIRO Health and Biosecurity · AUUniversity of Newcastle Australia · AUFlinders University · AUUniversity of South Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma is a lethal form of brain tumour usually treated by surgical resection followed by radiotherapy and an alkylating chemotherapeutic agent. Key to the success of this multimodal approach is maintaining apoptotic sensitivity of tumour cells to the alkylating agent. This initial treatment likely establishes conditions contributing to development of drug resistance as alkylating agents form the O

Indexed as

Antineoplastic Agents, AlkylatingApoptosisDNA AdductsDNA Mismatch RepairDNA RepairDrug Resistance, NeoplasmGlioblastomaGuanineHumansMutationNeoplasm Recurrence, LocalAntineoplastic Agents, AlkylatingDNA AdductsGuanineO-(6)-methylguaninealkylating agentscellular resistanceDNA adductsDNA repairglioblastomaMGMTmismatch repairO6-methylguanine

Identifiers

PMID29020502
PMCPMC5718815
OpenAlexW2762363538

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.